SUSCEPTIBILITY TESTING OF YEASTS 2011

AGAR DIFFUSION METHOD WITH NEO-SENSITABS

- USING MUELLER-HINTON AGAR WITH 2% GLUCOSE AND 0.5 μ G/ML METHYLENE BLUE.



INTRODUCTION

CLSI (formerly NCCLS) has established a standard method for Antifungal Disk Diffusion Susceptibility Testing of Candida species(1) including fluconazole and voriconazole.

In recent studies (2,3,4) the correlation of Neo-Sensitabs with CLSI (formerly NCCLS) reference disk diffusion and Broth Microdilution Method was demonstrated.

Neo-Sensitabs thus offers an economical method to perform reliable antifungal susceptibility testing.

The technique for susceptibility testing of yeast differs from traditional antibiotic susceptibility testing, and requires more experience, especially when reading the zone sizes. Experience results in greater accuracy.

Species identification is recommended in addition to susceptibility testing.

This folder is intended to give the user practical guidance on the procedure and how to read the zones.



AGAR MEDIA:

MUELLER-HINTON WITH 2% GLUCOSE AND 0.5 μ G/ML METHYLENE BLUE

The addition of glucose provides a suitable fungal growth and the methylene blue dye enhances zone edge definition.

It is important that the medium supports adequate growth, otherwise zones obtained with Neo- Sensitabs will be larger than normal.

-INOCULUM - INOCULATION OF THE AGAR PLATE - INCUBATION TIME

Equivalent to 0.5 McFarland standard - the inoculum should result in semi- confluent growth with most Candida species isolates.
IMPORTANT: Using a standardised inoculum is very important. Too heavy inoculum makes reading of the zones for the Imidazoles/Azoles difficult and may lead to susceptible strains being considered falsely resistant. Make sure that zone diameters of quality control strains are in range.
Dip a sterile cotton swab into the suspension – rotate several times. Remove excess fluid from the swab by pressing firmly against the inside wall above the fluid level. Inoculate the dried surface of the agar by streaking the cotton swap according to
the standard method. Ensure an even distribution of the inoculum. The plate may be left open for 3 – 5 minutes, allowing excess moisture to be absorbed, before dispensing the Neo-Sensitabs onto the plate.
Incubation at 35 °C \pm 1°C within 15 minutes after the Neo-Sensitabs have been applied.
Reading of zones: 20 – 24 hours after incubation.
Always examine the plates after overnight incubation – measure the inhibition zones if visible. If no visible growth with particular strains, reincubate for up to 24 hours more.

INTERPRETATION TABLE** (SYSTEMIC)

				Zone diameter in mm			Break-points MIC µg/ml	
Ref. No.	Neo-Sensitabs	Potency	Code	S	l I	R	S	R
82512	Fluconazole	25 µg	FLUCZ	≥ 19	18 – 15 (DD)	≤14	≤8	≥64
82312	Voriconazole	1 µg	VOR.1	≥ 17	16 - 14 (DD)	≤13	≤ 1	≥ 4
81012	Amphotericin B	10 µg	AMPH	≥ 15	14 – 10	< 10	≤ 1	≥2
81812	Itraconazole	10 µg	ITRAC	≥ 23	22 – 14 (DD)	< 13	≤ 0.12	≥ 1
81912	Ketoconazole	15 µg	KETOC	≥ 28	27 – 21	≤20	≤ 0.12	≥0.5
82412	Caspofungin*	5 µg	CASP5	≥ 16	15 – 13	≤12	≤ 0.25	≥ 1
82612N	Posaconazole	5 µg	POSAC	≥ 17	16 – 14(DD)	≤13	≤1	≥ 4

DD = dosis dependent

** Potencies of antifungals, MIC breakpoints and zone breakpoints as recommended by CLSI for Fluconazole and Voriconazole (1). For Amphotericin B, Itraconazole, Ketoconazole and Posaconazole the MIC breakpoints recommended by CLSI are used.



INTERPRETATION TABLE. LOCAL TREATMENT

S	≥ 20 mm	≥ 15 mm	≥ 10 mm
l.	12 – 19 mm	10 – 14 mm	-
R	≤ 11 mm	No zone	No zone
	Ciclopirox, Clotrimazole, Econazole, Miconazole, Terbinafine, Fluorocytosine 1 µg (Shadomy agar)	Nystatin	Griseofulvin

READING OF THE ZONES

For the best reading the plates are held above a black, nonreflecting background which is illuminated with reflected light.

1. AZOLES (e.g. Fluconazole, Itraconazole, Voriconazole, Ketoconazole, Posaconazole)

For azoles the zones must be measured up to colonies of normal size (fig 1.)






Fig. 1: Sensitive C. albicans

Fig. 2: Resistant C. albicans

There is often a zone of growth of partially inhibited colonies whose sizes are smaller nearer the tablet than at the edge of the real zone. These small and medium-size colonies are not resistant mutants.

2. POLYENES (e.g. Amphotericin B)

For Polyenes the clear zone with no visible growth is measured (fig 3.)



Fig 3. Sensitive C. albicans



Fig. 4: Resistant C. albicans

Note: If there are colonies inside the zone, they must be considered resistant mutants.



QUALITY CONTROL - INHIBITION ZONE IN MM, M H AGAR + 2 % GLUCOSE + METHYLENBLUE

	Fluconazole 25 μg	Voriconazole 1 µg	ltraconazole 10 μg	Ketoconazole 15 μg	Amphotericin Β 10 μg	Posaconazole 5µg	Caspofungin 5µg
C. albicans ATCC 90028	28 – 39	31 – 42	21 – 30	31 – 42	20 – 27	24 – 34	15 – 22
C. parapsilosis ATCC 22019	22 – 33	28 - 37	19 – 26	26 - 35	22 – 29	25 - 36	13 – 23
C. krusei ATCC 6258	-	23 – 31	16 – 22	22 – 29	18 – 25	23 – 31	16 – 22
	Ciclopirox 50 µg	Clotrimazole 10 µg	Econazole 10 μg	Miconazole 10 μg	Terbinafine 30 μg	Nystatin 50 μg	
C. albicans ATCC 90028	22 – 30	28 – 36	19 – 26	22 – 29	9 - 9	20 - 26	
C. parapsilosis ATCC 22019	20 – 28	30 - 38	11 – 18	13 – 20	26 - 34	22 – 28	
C. krusei ATCC 6258	22 – 29	26 - 34	9 – 15	11 – 18	9-9	18 – 24	

THE WIDEST BANGE AVAILABLE

The currenct Neo-Sensitabs product range includes antifungal agents for systemic as well as for local treatment:

REF. No.	Product	Code	Potency µg
81012	Amphotericin B	AMPHO	10 *
81112	Ciclopirox	CICLO	50
81212	Clotrimazole	CTRIM	10
82412	Caspofungin	CASP5	5
81312	Econazole	ECONZ	10
82512	Fluconazole	FLUCZ	25
81512	Fluorocytosine 1 µg	FLU.1	1
81712	Griseofulvin	GRISE	25
81812	Itraconazole	ITRAC	10
81912	Ketoconazole	KETOC	15
82012	Miconazole	MICOZ	10
82212	Nystatin	NYSTA	50
87412	Terbinafine	TERBI	30
82312	Voriconazole	VOR.1	1
82612N	Posaconazole	POSAC	5



Caspofungin A new antifungal added to the Neo-Sensitabs range.

* = store at 2 - 8° C

References:

NCCLS 2008. Method for antifungal disk diffusion susceptibility testing of yeasts. Approved Sandard M44-A2.

Rementeria A. et al. Utility of Neo-Sensitiabs tablets of Fluconazone and Voriconazole for in vitro susceptibility testing of *Candida* spp. with the NCCLS M44-P method of diffusion on agar. Ill Congress Mycology, Salamanca, July 2004 (Spanish).

3. Espinel-Ingroff A. et al: Correlation between Neo-Sensitabs tablets on 3 media, NCCLS disk diffusion and broth microdilution methods for testing Candida spp. and C. neoformans with fluconazole and voriconazole. J. Clin. Microbiol. 45, 858-64, 2007.

Vanderbossche I. et al: Susceptibility testing of fluconazole by the NCCLS macrodilution method; E-test and disk diffusion methods. J. Clin. Microbiol, 40, 918-21, 2002.
NCCLS 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A2.

Carrillo-Muñoz AJ et al: Activity of Caspofungin and Voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M44A disk diffusion method with Neo-6.

Sensitabs tablets, Chemotherapy, 54 (1) 38-42, 2008 7. Espinel-Ingroff A et al: Multicenter evaluet of a new disk agar diffusion method for susceptibility testing of filamentous fungi with Voriconazole, Posaconazole, Itraconazole, Amphothericin B and

Caspofungin. J. Clin. Microbiol., 45, 1811-20, 2007 8. Espinel-Ingroff A et al: Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility filamentous fungi with Ampothericin B, caspofungin itraconazole, posaconazole and voriconazole. J. Clin. Microbial. 46, 1793-1803, 2008 Pujol I et al: Evaluetion of the Neo-Sensitabs[™] diffusion method for determining the antifungal susceptibility of Cryptococcus gattii isolates using 3 different agar media. Rev. Iberoam. Micol., 25,

9. 215-220, 2008

10. Carrillo-Muñoz AJ et al: Antifugal activity of Posaconazole against Candida app and non-Candida clinical yeast isolates. Rev. Esp Quimioter. 23, 122-125, 2010. 11 Ochiuzzi ME et al : Correlation of E-test and Neo-sensitabs diffusion assays on Mueller-Hinton methylene blue agar with broth microdilution Reference method (CLSI-M27 -A2) for testing susceptibility to Cryptococcus neoformans to Amphotericin B and fluconazole. Med Mycology 48,893-896,2010.

